Per Pfeiffer

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Eric Van Cutsem, Andrés Cervantes, René Adam et al. · Annals of Oncology · 2016 · 3.3K citations · Full text

Surgical Oncology, Esmo Consensus Guidelines, Gastrointestinal Oncology +9

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Retrospective Consortium Analysis, Medicine, Pathology +5

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten et al. · The Lancet Oncology · 2020 · 1.5K citations · Full text

Surgical Oncology, Radiation Therapy, Gastrointestinal Oncology +9

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein et al. · Annals of Oncology · 2012 · 1.5K citations · Full text

Esmo Consensus Guidelines, Personalized Approach, Gastrointestinal Oncology +9

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text